Evidence map›Paper›PMID 42287060›Full record

ArticleBeijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences2026

[Molecular characteristics for poor prognosis related renal cell carcinoma with lymph metastases].

Fan Shu, Liyuan Ge, Hanzhang Deng, Haoming Yin, Junyong Ou, Shaohui Deng, Yichang Hao, Min Lu, Zhanyi Zhang, Peichen Duan and 1 more

Abstract readEnglish Abstract
In one paragraph

Article in Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Fan ShuDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Liyuan GeDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Hanzhang DengDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Haoming YinDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Junyong OuDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Shaohui DengDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Yichang HaoDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Min LuDepartment of Pathology, Peking University Third Hospital, Beijing 100191, China.
Zhanyi ZhangDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Peichen DuanDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.
Shudong ZhangDepartment of Urology, Peking University Third Hospital, Beijing 100191, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveNext-generation sequencing (NGS) technology was used to analyze the gene mutation profile of lymph node metastases in renal cell carcinoma, and the molecular characteristics associated with poor prognosis were found, providing new ideas for mechanism research and treatment.

methodsRetrospective clinical data collection was conducted on 31 patients with lymphoid metastatic renal cell carcinoma and 21 patients with non-metastatic renal cell carcinoma. A total of 81 formalin-fixed paraffin-embedded tissue samples were retrieved from the Department of Pathology, including primary tumor, lymph node metastasis, and distant metastasis samples. The gene mutation profiles of the patients were examined using next-generation sequencing technology. The patients were followed up to analyze the correlation between lymph node metastasis and patient prognosis.

resultsThe lymph node metastasis group showed differences in tumor size (

conclusionThe multigene NGS evaluates multiple relevant markers simultaneously, revealing several genetic alterations in the patients with lymphatic metastatic renal cell carcinorma. NGS-based molecular analysis can assist clinicians in assessing a patient' s prognosis and identifying novel, potentially therapeutic mechanisms.

Indexed as

Carcinoma, Renal CellKidney NeoplasmsLymphatic MetastasisMutationAdultAgedFemaleHigh-Throughput Nucleotide SequencingHumansMaleMiddle AgedPrognosisRetrospective StudiesDNA mutational analysisHigh-throughput nucleotide SequencingLymphatic metastasisPrognosisRenal cell carcinoma

Identifiers

PMID42287060
PMCPMC13268807

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.